文献速递腹部技术与安全USMR

全氟丁烷增强超声诊断高危患者小肝癌:与MRI LI-RADS 2018版比较

Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.
PubMed 文献 · Radiology · 2026-01-01

这项多中心回顾性研究纳入365例高危患者共399个≤20 mm肝脏结节,比较全氟丁烷增强超声两种策略与MRI LI-RADS 2018版诊断小肝癌的性能。策略B(纳入Kupffer期低增强)敏感度高于策略A(65.9% vs 57.1%,P<.001),特异度无下降证据;策略B与MRI敏感度和特异度均无差异证据。

要点

  • 全氟丁烷增强超声策略B(含Kupffer期低增强)诊断小肝癌敏感度65.9%,特异度91.8%。
  • 策略B敏感度高于策略A(65.9% vs 57.1%,P<.001),特异度无下降证据(P=.07)。
  • 策略B与MRI LI-RADS 2018版敏感度、特异度均无差异证据(P=.07、P=.59)。

核心结论

  • 在高危患者中,纳入Kupffer期表现的全氟丁烷增强超声对诊断小肝癌有效,诊断性能与MRI相似。

研究设计与样本

  • 多中心回顾性研究,纳入2020年3月至2023年11月高危患者365例(中位年龄54岁,IQR 47-61岁;310例男性),共399个观察灶(中位直径16 mm,IQR 12-19 mm;252个HCC、41个非HCC恶性肿瘤、106个良性结节),比较全氟丁烷增强超声策略A、策略B与MRI LI-RADS 2018版的诊断性能,采用广义估计方程方法。

诊断标准与关键数值

  • 策略A依据CEUS LI-RADS 2017版LR-5标准:观察灶至少10 mm、非环状动脉期高增强,注射后5分钟内评估晚期轻度廓清;策略B在策略A基础上扩展纳入10 mm及以上、非环状动脉期高增强、5分钟内无廓清且Kupffer期低增强的观察灶。策略B敏感度65.9%(166/252)vs 策略A 57.1%(144/252),P<.001;策略B特异度91.8%(135/147)vs 策略A 93.9%(138/147),P=.07。策略B vs MRI敏感度65.9%(166/252)vs 72.6%(183/252),P=.07;特异度91.8%(135/147)vs 90.5%(133/147),P=.59。无肝硬化 vs 肝硬化患者:策略A特异度97.4%(76/78)vs 89.9%(62/69),策略B特异度96.2%(75/78)vs 87.0%(60/69),均P=.04;策略A敏感度54.8%(46/84)vs 58.3%(98/168),P=.63;策略B敏感度61.9%(52/84)vs 67.9%(114/168),P=.39。

临床应用与阅片要点

  • 在高危患者中,全氟丁烷增强超声纳入Kupffer期低增强表现(策略B)可提高小肝癌诊断敏感度,且诊断性能与MRI LI-RADS 2018版相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Evidence supporting the incorporation of perfluorobutane (PFB) contrast-enhanced US (CEUS) into Liver Imaging Reporting and Data System (LI-RADS) in diagnosing small hepatocellular carcinoma (HCC) (≤20 mm) in patients at high risk for HCC remains limited. Purpose To compare diagnostic performance of PFB CEUS and MRI for small HCC in high-risk patients. Materials and Methods This multicenter retrospective study included high-risk patients who underwent PFB CEUS and concurrent MRI for evaluating liver nodules 20 mm or smaller from March 2020 to November 2023. PFB CEUS strategy A followed LR-5 criteria based on CEUS LI-RADS version 2017: observations that were at least 10 mm with nonrim arterial-phase hyperenhancement (APHE), with late and mild washout assessed up to 5 minutes postinjection; strategy B expanded on strategy A by also incorporating observations 10 mm or larger with nonrim APHE, no washout up to 5 minutes, and hypoenhancement on Kupffer-phase images. The diagnostic performance of these two CEUS strategies and MRI LI-RADS version 2018 was compared using a generalized estimating equations approach. Results A total of 365 patients (median age, 54 years; IQR, 47-61 years; 310 men) with 399 observations (median diameter, 16 mm; IQR, 12-19 mm; 252 HCCs, 41 non-HCC malignancies, 106 benign nodules) were included. Strategy B yielded higher sensitivity than strategy A (65.9% [166 of 252] vs 57.1% [144 of 252]; P < .001) without evidence of a decrease in specificity (91.8% [135 of 147] vs 93.9% [138 of 147]; P = .07). Compared with MRI, strategy B showed no evidence of a difference in sensitivity (65.9% [166 of 252] vs 72.6% [183 of 252]; P = .07) and specificity (91.8% [135 of 147] vs 90.5% [133 of 147]; P = .59). Strategies A and B showed higher specificity (97.4% [76 of 78] vs 89.9% [62 of 69]; 96.2% [75 of 78] vs 87.0% [60 of 69], respectively; both P = .04) but no evidence of a difference in sensitivity (54.8% [46 of 84] vs 58.3% [98 of 168] [P = .63]; 61.9% [52 of 84] vs 67.9% [114 of 168] [P = .39], respectively) in patients without cirrhosis versus in patients with cirrhosis. Conclusion In patients at high risk for HCC, PFB CEUS incorporating Kupffer-phase findings was effective for diagnosing small HCC, with diagnostic performance similar to MRI. © RSNA, 2026 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Li Y, Lu S, Mao S, et al. Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018. Radiology. 2026. PMID: 41773972. doi:10.1148/radiol.252271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。